Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
- Resource Type
- Short Communication
- Source
- In
JAAD International March 2022 6:3-5 - Subject
Research letter - Language
- ISSN
- 2666-3287